AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03182790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instant Messaging IM
Description: Smokers can communicate with counsellors in real-time through instant messaging (social media). Our counsellors will trigger the conversation and invite the smokers to response after initial contact. Counsellors will keep contact with the smokers to offer help, positive encouragement, reflections and reminders about SC according to smokers' personal needs and to encourage them to seek SC services. Details of successfully booked SC appointment (e.g. SC services address, contact information, date, appointment number etc.) will be delivered to the smokers using IM. All smokers will receive a reminder-to-attend IM messages 1-3 days before the appointment date.
Study NCT03182790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular messages
Description: Regular messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent to smokers after initial contact via social media.
Study NCT03182790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
Study NCT03182790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans
Study NCT03182790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice
Description: Very brief, minimal and general smoking cessation advice
Study NCT03182790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH booklet
Description: A general smoking cessation self-help booklet
Study NCT03182790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Messages
Description: Placebo messages will be sent via smart phones (e.g. social media) to remind subjects to take follow-up calls before each follow-up time points.
Study NCT03182790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning Leaflet
Description: The leaflet will include the information about the health risks of smoking.
Study NCT02166359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extraneal (Icodextrin)
Study NCT02166359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose solution
Study NCT01944748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Able To Resolve Situations (FARS)
Description: Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
Study NCT02465164 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cook catheter
Study NCT02465164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook catheter
Study NCT02465164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT02324361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
Study NCT02324361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based information on healthy family routines
Description: Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
Study NCT05651386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: No blinded, no controlled intervention.
Study NCT01948921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01948921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Study NCT02568462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Description: Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
Study NCT00490516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-104
Description: 200 mg, tablet, BID, 6 weeks
Study NCT00490516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-104
Description: 100 mg, tablet, BID, 6 weeks
Study NCT00490516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, tablet BID, 6 weeks
Study NCT01189877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eppendorf hypoximeter
Description: Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
Study NCT02390089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin vapor
Description: Single-breath and continuous inhalation paradigm to induce cough.
Study NCT02390089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin vapor
Description: Single-breath and continuous inhalation paradigm to induce cough.
Study NCT02390089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fog
Description: Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
Study NCT02390089 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallow evaluation
Description: Fluoroscopic evaluation of oropharyngeal swallowing function.
Study NCT02390089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer
Description: A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
Study NCT02390089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulizer
Description: A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
Study NCT01454011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosteron 250mg injection
Description: The combination of 4 different testosterone esthers (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate) injected in 3 weeks intervals.
Study NCT01454011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 50mg transdermal application
Description: Application of testosterone 50mg transdermal gel in every night
Study NCT02638987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
Study NCT02256813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX
Study NCT02256813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Study NCT02256813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT02256813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide
Study NCT02256813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT02256813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam hydrochloride
Study NCT02256813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K1
Study NCT03513263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and polishing
Description: An electronic scaler will be used to clean the gums
Study NCT03513263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral hygiene instructions
Description: It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning
Study NCT03513263 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: oral hygiene instructions
Description: It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning
Study NCT03442647 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: sinistrin clearance dynamic measurement
Description: sinistrin clearance measurements will be performed before and 90 min after oral protein load
Study NCT03653845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular chemical Ablation of Adrenal Gland
Description: Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
Study NCT03653845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequenced antihypertensvie drugs with titrated dosage
Description: Patients will be treated with different antihypertensive drugs in two groups.
Study NCT03653845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequenced antihypertensvie drugs with titrated dosage
Description: Patients will be treated with different antihypertensive drugs in two groups.
Study NCT04143191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.
Study NCT04143191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.
Study NCT04143191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: TACE including conventional TACE (cTACE) and DEB-TACE. Treatment choices are according to the specific condition of each patient and the experience of interventional radiologists.
Study NCT02251821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplant
Study NCT02251821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT02251821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02251821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02251821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02251821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02251821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT02251821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT02251821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT02251821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT02251821 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT02251821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo umbilical cord blood transplant
Study NCT05005624 — intervention group
Intervention type: OTHER
Intervention: ADL performance
Description: All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc
Study NCT02571764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Oats Cookie
Study NCT05932771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Consumption of three different doses of hydrolyzed collagen (HC) with reistance exercise
Description: Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)
Study NCT05932771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise
Description: Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams maltodextrin was used in 0 grams HC. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)
Study NCT03746639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy modalities
Description: The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 .
Study NCT03746639 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy modalities
Description: The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 .
Study NCT01801111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
Study NCT01801111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
Study NCT01174108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi CD34 Reagent System
Description: The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.
Study NCT01174108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor derived G-CSF mobilized PBC
Description: Cell Therapy
Study NCT04284826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture
Study NCT03189355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: * D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube~* D4 zonulin
Study NCT03189355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance vector analysis
Description: * D1~* D4
Study NCT03189355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscular echography
Description: * D1~* D4
Study NCT01545141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemokin Modulatory Regimen (5 MU/m2)
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
Study NCT01545141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemokin Modulatory Regimen (10 MU/m2)
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
Study NCT01545141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemokin Modulatory Regimen (20 MU/m2)
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
Study NCT04501055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perineal nerve block
Description: An anesthesia method to block perineal nerve
Study NCT04501055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: periprostatic block
Description: An anesthesia method to block periprostate
Study NCT00769262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative weaning
Description: Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
Study NCT00769262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Weaning
Description: Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
Study NCT03852823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Phase Ia: Subjects will receive intravenous infusion of SG001 following a sequential dose escalation design (1mg/kg, 3mg/kg and 10mg/kg). Dose limited toxicity (DLT) will be observed within 21 days after the first administration, then subjects can continuously receive SG001 every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial. Phase Ib: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial.